Implementation of a Face-To-Face Vs Virtual Peer-Integrated Collaborative Care Intervention for Mental Health Treatment of Physical Trauma Survivors: A Qualitative Study of Lessons from the COVID-19 Pandemic.

PsychiatryNov 25, 2025 (epub)
Clinical ResearchPsychiatry

Lawrence A Palinkas, Allison Engstrom, Tanya Knutsen et al.

✦ AI-curated · Sources linked

In 30 seconds

This qualitative study examined how the COVID-19 pandemic affected implementation of a peer-integrated collaborative care intervention for mental health among 450 patients receiving treatment for physical injuries. Seven clinician investigators used participant observation in a trauma care setting at a major US metropolitan hospital, with analysis involving an external mixed-methods specialist. Pandemic-related pressures and service changes created or worsened implementation barriers, including a temporary reduction in intervention reach. Although peer specialists felt virtual contact reduced their effectiveness, patient satisfaction assessments did not reflect this concern, and virtual delivery may have improved some implementation outcomes.

Key findings

  • Pandemic-related service pressures and safety measures created or worsened multiple barriers, including provider shortages, recruitment suspension, scheduling difficulties, and increased interventionist workload.
  • The intervention’s reach to its target population declined temporarily.
  • Peer specialists perceived virtual interactions as less effective, but this was not reflected in patient satisfaction assessments.
  • Virtual delivery may have improved some implementation outcomes, including adoption by Trauma Center staff.

Why it matters

The findings illustrate how public health emergencies can disrupt delivery of evidence-based mental health care in trauma settings through both system pressures and changes in how patients are reached. They also suggest that perceived loss of effectiveness with virtual contact may not align with patient satisfaction or all implementation outcomes, underscoring the value of assessing multiple perspectives when services change.

What to keep in mind

The findings are qualitative and based on participant observation by clinician investigators at one major metropolitan hospital, limiting generalisability.

Source

Published in Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.